BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24075699)

  • 1. Value and payment for oncology in the United States.
    Robinson JC
    Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing physician incentives for affordable, quality cancer care: results of an episode payment model.
    Newcomer LN; Gould B; Page RD; Donelan SA; Perkins M
    J Oncol Pract; 2014 Sep; 10(5):322-6. PubMed ID: 25006221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current issues in oncology reimbursement.
    Bailes JS
    Oncology (Williston Park); 1995 Nov; 9(11 Suppl):185-9. PubMed ID: 8608051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new Medicare bill: far-reaching effects on cancer treatment.
    Bailes JS; Coleman T
    Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long battle over payment for oncology services in the office setting.
    Bailes JS; Coleman TS
    J Oncol Pract; 2014 Jan; 10(1):1-4. PubMed ID: 24443726
    [No Abstract]   [Full Text] [Related]  

  • 6. Design Challenges of an Episode-Based Payment Model in Oncology: The Centers for Medicare & Medicaid Services Oncology Care Model.
    Kline RM; Muldoon LD; Schumacher HK; Strawbridge LM; York AW; Mortimer LK; Falb AF; Cox KJ; Bazell C; Lukens EW; Kapp MC; Rajkumar R; Bassano A; Conway PH
    J Oncol Pract; 2017 Jul; 13(7):e632-e645. PubMed ID: 28535101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reimbursement: current status and future outlook.
    Bailes JS
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):118-22. PubMed ID: 8091237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential approaches to sustainable, long-lasting payment reform in oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):254-8. PubMed ID: 24737874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to create successful alternative payment models in oncology.
    Miller HD
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP160-SP163. PubMed ID: 28665673
    [No Abstract]   [Full Text] [Related]  

  • 11. Value-based payment models in oncology: will they help or hinder patient access to new treatments?
    Shah S; Reh G
    Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP188-SP190. PubMed ID: 28665677
    [No Abstract]   [Full Text] [Related]  

  • 12. Seeking value as cancer drug costs soar.
    Bender E
    Cancer Discov; 2013 Aug; 3(8):833-4. PubMed ID: 23928760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The shortage of essential chemotherapy drugs in the United States.
    Gatesman ML; Smith TJ
    N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
    [No Abstract]   [Full Text] [Related]  

  • 14. The adequacy of physician reimbursement for pediatric care under Medicaid.
    McManus M; Flint S; Kelly R
    Pediatrics; 1991 Jun; 87(6):909-20. PubMed ID: 2034498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. United healthcare, five oncology practices try bundled payments.
    Goozner M
    J Natl Cancer Inst; 2011 Jan; 103(1):8-10. PubMed ID: 21169535
    [No Abstract]   [Full Text] [Related]  

  • 16. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reforming the payment system for medical oncology.
    Bach PB
    JAMA; 2013 Jul; 310(3):261-2. PubMed ID: 23817729
    [No Abstract]   [Full Text] [Related]  

  • 18. Insurers and oncologists forge a better cancer drug policy.
    Butcher L
    Manag Care; 2008 Apr; 17(4):28-30. PubMed ID: 18464570
    [No Abstract]   [Full Text] [Related]  

  • 19. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of cancer care: a view from the centers for Medicare and Medicaid services.
    Bach PB
    J Clin Oncol; 2007 Jan; 25(2):187-90. PubMed ID: 17210938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.